Regenxbio Faces Class Action for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy RGNX?
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant treated in the RGX-111 study further confirms the company's concealment of product safety, potentially eroding investor confidence and affecting future financing capabilities for the company.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to participate in the lawsuit to seek compensation, highlighting the legal avenue available for investors to recover their losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.420
Low
19.00
Averages
29.71
High
45.00
Current: 10.420
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
REGENXBIO to Present Gene Therapy Advances at ASGCT 2026 Meeting
- Conference Presentation: REGENXBIO will showcase advancements in its NAVXpress® manufacturing platform at the 2026 ASGCT Annual Meeting, highlighting pivotal data from its RGX-202 gene therapy for Duchenne muscular dystrophy, which is expected to attract industry attention and foster future collaborations.
- Oral Presentation Schedule: Featuring a talk by Dr. Metewo Selase Kosi Enuameh on AAV manufacturability scheduled for May 14, this presentation underscores REGENXBIO's technological leadership in gene therapy, potentially enhancing its market recognition.
- Poster Presentation Highlights: The company will present several posters, including research on NVG82 for outer retinal gene transfer, which is anticipated to demonstrate its unique capsid engineering capabilities, further solidifying its market position in rare disease treatments.
- Future Development Potential: REGENXBIO's gene therapies are poised to transform healthcare delivery, and as clinical trials progress, they are expected to provide new treatment options for thousands of patients, thereby enhancing the company's competitiveness in the biotechnology sector.
See More
REGENXBIO to Report Q1 2026 Financial Results
- Webinar Announcement: REGENXBIO will host a webcast on May 14, 2026, at 8:00 AM ET to discuss topline results from the pivotal trial of RGX-202, its next-generation gene therapy for Duchenne muscular dystrophy, featuring prominent Duchenne physicians to enhance industry influence.
- Financial Results Release: The company will also report its Q1 2026 financial results and operational highlights on the same day, expected to provide critical insights into the company's financial health and future outlook, potentially impacting investor confidence.
- Gene Therapy Advancements: REGENXBIO is advancing its late-stage pipeline for rare and retinal diseases, including RGX-121 and RGX-111 in partnership with Nippon Shinyaku, showcasing the company's ongoing innovation and market potential in gene therapy.
- Patient Treatment Impact: REGENXBIO's AAV platform has treated thousands of patients, including those receiving Novartis' ZOLGENSMA®, indicating that its gene therapies have the potential to transform healthcare delivery for millions, further solidifying its market position.
See More
REGENXBIO to Report Q1 2026 Financial Results on May 14
- Webcast Announcement: REGENXBIO will host a webcast on May 14, 2026, at 8:00 AM ET to discuss pivotal trial results for RGX-202, its next-generation gene therapy for Duchenne muscular dystrophy, featuring leading physicians which enhances the company's credibility in gene therapy.
- Financial Results Release: The company will also report its Q1 2026 financial results and operational highlights on the same day, providing investors with insights into its financial health, which could influence market expectations regarding its growth potential.
- Pipeline Progress: REGENXBIO is advancing a late-stage pipeline for rare and retinal diseases, including RGX-121 and RGX-111 in partnership with Nippon Shinyaku, showcasing its ongoing innovation and competitive edge in the gene therapy sector.
- Patient Treatment Impact: The company has treated thousands of patients with its AAV platform, including those receiving Novartis' ZOLGENSMA®, indicating that its gene therapies have the potential to transform healthcare delivery for millions, further solidifying its leadership in the biotechnology industry.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors seeking justice.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
FDA Leadership Shakeup May Impact Biotech Stocks
- Stock Price Surge: Following reports of potential dismissal of FDA Commissioner Marty Makary, shares of Replimune (REPL) and uniQure (QURE) surged by 17% and 15% respectively, indicating market optimism regarding regulatory improvements under new leadership.
- Industry Response: The pharmaceutical industry has expressed dissatisfaction with Makary's drug review policies, citing inconsistencies and overly restrictive processes that hinder innovative drug approvals, suggesting that new leadership could accelerate approval timelines and restore clearer regulatory guidance.
- Potential Beneficiaries: Companies like Replimune and uniQure, which have publicly clashed with the FDA, are seen as potential beneficiaries of new leadership, with Replimune's melanoma therapy RP1 being rejected and uniQure's Huntington's disease gene therapy AMT-130 facing significant shifts in review policy.
- Market Reaction: Despite REPL's stock falling approximately 50% over the past year, QURE's stock has risen by 124%, reflecting investor confidence in the future of the biotech sector and expectations for changes in FDA policies.
See More
REGENXBIO to Present Gene Therapy Advances at ASGCT 2026 Meeting
- Conference Presentation: REGENXBIO will showcase advancements in its NAVXpress® manufacturing platform at the 2026 ASGCT Annual Meeting, highlighting pivotal data from its RGX-202 gene therapy for Duchenne muscular dystrophy, which is expected to attract industry attention and foster future collaborations.
- Oral Presentation Schedule: Featuring a talk by Dr. Metewo Selase Kosi Enuameh on AAV manufacturability scheduled for May 14, this presentation underscores REGENXBIO's technological leadership in gene therapy, potentially enhancing its market recognition.
- Poster Presentation Highlights: The company will present several posters, including research on NVG82 for outer retinal gene transfer, which is anticipated to demonstrate its unique capsid engineering capabilities, further solidifying its market position in rare disease treatments.
- Future Development Potential: REGENXBIO's gene therapies are poised to transform healthcare delivery, and as clinical trials progress, they are expected to provide new treatment options for thousands of patients, thereby enhancing the company's competitiveness in the biotechnology sector.
See More
REGENXBIO to Report Q1 2026 Financial Results
- Webinar Announcement: REGENXBIO will host a webcast on May 14, 2026, at 8:00 AM ET to discuss topline results from the pivotal trial of RGX-202, its next-generation gene therapy for Duchenne muscular dystrophy, featuring prominent Duchenne physicians to enhance industry influence.
- Financial Results Release: The company will also report its Q1 2026 financial results and operational highlights on the same day, expected to provide critical insights into the company's financial health and future outlook, potentially impacting investor confidence.
- Gene Therapy Advancements: REGENXBIO is advancing its late-stage pipeline for rare and retinal diseases, including RGX-121 and RGX-111 in partnership with Nippon Shinyaku, showcasing the company's ongoing innovation and market potential in gene therapy.
- Patient Treatment Impact: REGENXBIO's AAV platform has treated thousands of patients, including those receiving Novartis' ZOLGENSMA®, indicating that its gene therapies have the potential to transform healthcare delivery for millions, further solidifying its market position.
See More
REGENXBIO to Report Q1 2026 Financial Results on May 14
- Webcast Announcement: REGENXBIO will host a webcast on May 14, 2026, at 8:00 AM ET to discuss pivotal trial results for RGX-202, its next-generation gene therapy for Duchenne muscular dystrophy, featuring leading physicians which enhances the company's credibility in gene therapy.
- Financial Results Release: The company will also report its Q1 2026 financial results and operational highlights on the same day, providing investors with insights into its financial health, which could influence market expectations regarding its growth potential.
- Pipeline Progress: REGENXBIO is advancing a late-stage pipeline for rare and retinal diseases, including RGX-121 and RGX-111 in partnership with Nippon Shinyaku, showcasing its ongoing innovation and competitive edge in the gene therapy sector.
- Patient Treatment Impact: The company has treated thousands of patients with its AAV platform, including those receiving Novartis' ZOLGENSMA®, indicating that its gene therapies have the potential to transform healthcare delivery for millions, further solidifying its leadership in the biotechnology industry.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors seeking justice.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases effectively.
See More
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
See More
